The paraventricular nucleus (PVN) of the hypothalamus plays a crucial role in cardiovascular and neuroendocrine regulation. Application of nitric oxide donors to the PVN stimulates GABAergic transmission, and may suppress sympathetic nerve activity (SNA) to lower arterial pressure.
INTRODUCTION
The paraventricular nucleus (PVN) of the hypothalamus is known to play a key role in the central regulation of sympathetic tone in health and disease (Caverson, Ciriello, & Calaresu, 1984; Ciriello & Calaresu, 1980; Coote, Yang, Pyner, & Deering, 1998; Kenney, Weiss, & Haywood, 2003; Patel, 2000; Pyner & Coote, 2000; Ranson, Motawei, Pyner, & Coote, 1998; Saper, Loewy, Swanson, & Cowan, 1976; Swanson & Sawchenko, 1983) . Recently, there has been a particular focus on the regulatory role of nitric oxide within the PVN (Li, Chen, & Pan, 2002a; Li, Roy, Channon, Zucker, & Patel, 2002b; Pyner, 2009; Sharma, Zheng, Mehta, Li, & Patel, 2011; Wang, Liu, Cornish, Zucker, & Patel, 2005; Watkins, Cork, & Pyner, 2009 Neuronal nitric oxide synthase (nNOS) is the enzyme largely responsible for the production of nitric oxide in neurones and is expressed in a number of brain regions important in autonomic control, including the PVN (Garthwaite & Boulton, 1995) . Expression of nNOS in the PVN has been shown to be reduced in sympathoexcitatory diseases, including heart failure (Pyner, 2014; Schultz, 2009; Zhang, Zucker, & Patel, 1998) and chronic intermittent hypoxia-induced hypertension (Huang, Tamisier, Ji, Tong, & Weiss, 2007) . In contrast, nNOS expression is increased in the PVN of spontaneously hypertensive (Plochocka-Zulinska & Krukoff, 1997) and renovascular hypertensive rats (Krukoff, Gehlen, Ganten, & Wagner, 1995) , where it is hypothesized to compensate for the sympathetic hyperactivity characteristic of these models.
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wileyonlinelibrary.com/journal/ephFunctionally, experimental approaches that either increase neuronal excitability or decrease nitric oxide transmission in the PVN tend to increase sympathetic drive and arterial blood pressure, at least as observed in the acute setting (Hirooka, Kishi, Sakai, Takeshita, & Sunagawa, 2011; Kannan, Hayashida, & Yamashita, 1989; Li, Mayhan, & Patel, 2001; Martin & Haywood, 1992) . In conscious rats, the shortterm blockade of nNOS transmission, by the infusion of nNOS-specific antisense oligonucleotides into the PVN, has been shown to produce increases in blood pressure and heart rate for several hours (Wang et al., 2005) , with evidence that a reduction in nitric oxide transmission in the PVN may contribute to sympathoexcitation in heart failure . Conversely, acute treatments that either increase synaptic inhibition or increase nitric oxide transmission in the PVN produce decreases in sympathetic drive and blood pressure (Akine, Montanaro, & Allen, 2003; Li et al., 2002b; . These functional data, together with neuroanatomical findings (Watkins et al., 2009) , suggest that nNOS-derived nitric oxide in the PVN plays a key role in the acute regulation of sympathetic outflow and arterial pressure.
Taken together, these data suggest an important role for nNOS in the PVN in regulation of the sympathetic outflow in both health and disease (Coote, 2005) . However, direct evidence that endogenous nNOS activity in the PVN plays a role in the long-term physiological regulation of cardiovascular sympathetic tone is lacking.
Previous studies examining a role for nitric oxide in the PVN for sympathetic control have been largely limited to acute effects, observed over a scale of minutes or hours in anaesthetized animals (Zhang, Li, & Patel, 2001; Zhang, Mayhan, & Patel, 1997) . Studies incorporating a longer time scale have involved nNOS overexpression in the PVN; however, interpretation here is confounded because cells that do not normally produce nNOS now express it, which might limit relevance to the physiological setting (Li et al., 2002b) . Thus, we set out to identify the role of nNOS in the PVN in determining longterm sympathetic outflow and cardiovascular control in conscious, unrestrained healthy rats. In order to produce a chronic decrease in endogenous levels of nNOS in the PVN, we have used our previously published lentiviral vector (LVV) knockdown system, reported to cause a ∼55% reduction in nNOS protein Liu, Xu, Paton, & Kasparov, 2010) .
METHODS

Ethical approval
All experiments were carried out according to the guidelines laid down by our institution's animal welfare committee and conform to the principles and regulations described by Grundy (2015) . 
Telemetric blood pressure and renal nerve recordings
Arterial pressure and renal sympathetic nerve activity (renal SNA)
were monitored continuously in rats using an implanted telemetric device (model TRBSNA; Telemetry Research Ltd, Auckland, New Zealand) as described by McBryde et al. (2013) . Briefly, rats were anaesthetized, and the abdominal aorta was exposed and cannulated immediately above the iliac bifurcation. The catheter was inserted until the tip rested immediately below the left renal artery branch point, and held in place using a tissue adhesive (VetBond; 3M, USA) and cellulose matrix. The transmitter body was placed in the abdominal cavity, and the electrode wire leads were tunnelled through to an incision on the left flank. The left renal artery was exposed via a retroperitoneal approach, and the renal nerves were gently freed from surrounding connective tissue and placed over the bipolar recording electrodes. The electrodes themselves were secured in place with sutures to the wall of the renal artery and abdominal aorta, and a biocompatible silicone elastomer (Kiwk-Sil; WPI, EU) used to isolate both electrode and nerve. The incisions were closed, and rats recovered for at least 7 days after surgery, with analgesic treatment once daily for 3 days (buprenorphine, 0.01 mg kg −1 per dose, Domitor, Elanco Animal Health, Hampshire, UK).
Arterial pressure and renal SNA signals were sampled at 500 Hz using an analog-to-digital data acquisition card (PCI 6024E; National Instruments, Austin, TX, USA) and displayed by a data acquisition program (Universal Acquisition 11; University of Auckland, Auckland, New Zealand). Heart rate (HR) was derived from the interpulse interval of the arterial pressure waveform. The renal SNA signal was amplified, filtered between 50 and 5000 Hz, full-wave rectified and integrated using a low-pass filter with a 20 ms time constant. At least 7 days were allowed for recovery before a 3 day baseline period was recorded.
Arterial pressure, renal SNA and HR were recorded for 24 h a day as 2 s averages, with high-frequency (500 Hz) periods of 5 min saved every hour to verify signal quality. Two days before and 7 days after lentiviral injection, rats were briefly exposed to a bolus of cigarette smoke (5 ml in air), which activates the nasopharyngeal nerve endings and provokes a powerful reflex increase in renal SNA. The magnitude of this response was used to check that the renal SNA signal remained viable and responsive throughout the experiment. The success rate for renal SNA recordings for the full experimental protocol (24 days) was ∼65%.
Lentiviral vector knockdown of nNOS in neurones
For nNOS knockdown, we used our binary LVV system, which has been validated previously in the hippocampus and dorsal vagal complex Liu, Wang, Brenner, Paton, & Kasparov, 2008) . This system requires co-operative action of two LVVs. This construct does not affect nNOS protein in vivo and will be referred to as LVV-control for simplicity.
Lentiviral vector protocol and microinjections
On day 0, rats were anaesthetized as described in section 2.1, placed in a stereotaxic frame using non-traumatic ear bars, and underwent bilateral microinjections of viral vectors (LVV-shRNA/nNOS and LVcontrol) into the PVN using glass micropipettes with tip diameters of ∼25 m. Microinjections were made 1.8 mm caudal to bregma, ±0.3 mm lateral to the mid-line and 7.5 mm below the dorsal surface of the cerebrum. Titres of both LVVs used were 2 × 10 9 to 6 × 10 9 Transducing Units (TU) ml −1 , with an injected volume of 0.5 l per site. The mean arterial pressure (MAP), HR and renal SNA were recorded for a further 21 days. In two rats injected with LVV-nNOS, the recording window was extended to 55 days to investigate the persistence of the observed pressor responses.
Owing to the known brain region differences in the efficacy of the viral system used and to validate the efficacy of nNOS knockdown in the PVN specifically, LVV-nNOS was microinjected unilaterally in a subgroup of rats (n = 3), and nNOS expression both compared and quantified immunocytochemically (see section 2.5) in the injected versus non-injected sides. For this, Fiji binary representation particle analysis of eGFP and nNOS was used to determine the percentage of each protein in both the left and right PVN regions.
Immunocytochemistry
Rats were terminally and deeply anaesthetized [induction with fluothane (Merial, Pirbright, UK), 5% in oxygen followed by sodium Vector Laboratories Ltd, UK) tagged with 1:500 streptavidin-AF594 (S11227; Molecular Probes, UK). All incubations were performed for 1 h at room temperature except the primary antibody incubation, which lasted for 24 h at 4 • C. Upon staining, the sections were mounted on Super frost slides, air dried at room temperature and coverslipped using Vectashield (H-1000; Vector Laboratories Ltd, UK). Slides were inspected on a Leica fluorescent microscope, under ×5-×20 magnification, and images captured with AxioVision software.
Omission of the primary antibody resulted in no detectable staining.
Data analysis
From the arterial pressure waveform, values for systolic, diastolic, mean and pulse pressure and HR were calculated. Spontaneous ramps in arterial pressure and HR were used to derive spontaneous cardiac baroreceptor reflex gain (sBRG), and low-and high-frequency spectral components of the blood pressure and HR signals were assessed to give indirect insight into changes in global autonomic tone, as described previously (Waki et al., 2006 
RESULTS
Cardiovascular response to nNOS knockdown
Baseline (days −3 to 0) MAP was similar between LVV-shRNA/nNOS and LVV-control rats (95 ± 5 versus 97 ± 6 mmHg, n.s.). As can be seen in Figure 1 , after microinjection of LVV-shRNA/nNOS on day 0 the MAP increased slowly from approximately day 7, reaching a stable plateau around day 10 (104 ± 7 mmHg; P = 0.041). The LVV-control animals showed no change in MAP throughout the entire experimental period. Figure 2a shows the individual data from a rat in which the blood pressure (BP) recording was continued until 55 days; in this rat, the blood pressure remained above baseline levels, as was found in a second rat that was followed until this extended time point.
Heart rate was not significantly different between LVV-shRNA/nNOS and LVV-control groups before viral microinjection (311 ± 27 versus 330 ± 45 beats min −1 , respectively) and did not change significantly in either group after viral microinjection. The increased BP persisted in the two LVV-shRNA/nNOS rats that were maintained for 55 days, which is consistent with the known long-acting expression of transgenes by lentiviruses (Naldini, Blomer, Gage, Trono, & Verma, 1996) . Figure 1 shows the temporal association between the increase in MAP and the concurrent increase in renal SNA in LVV-shRNA/nNOS rats.
Renal sympathetic response to nNOS knockdown
Renal SNA in LVV-shRNA/nNOS rats increased to >70% above baseline (+75 ± 44%, P = 0.034), whereas there was no significant change in LVV-control rats (−7 ± 37%, n.s.; Figures 2 and 3) . 
Baroreceptor reflex and heart rate variability
No change in the sBRG was seen with nNOS knockdown at baseline (LVV-control −6.7 ± 0.3 mmHg beat −1 min versus LVV-shRNA/nNOS −6.6 ± 0.5 mmHg beat −1 min, n.s.) or at week 3 (LVV-control −6.3 ± 0.3 mmHg beat −1 min versus LVV-shRNA/nNOS: −6.3 ± 0.5 mmHg beat −1 min, n.s.; Figure 3 ). Heart rate variability, as measured by the ratio of low-frequency and high-frequency power (LF:HF) of the pulse interval, showed a significant increase from baseline to week 3 in LVV-shRNA/nNOS rats (from 0.13 ± 0.08 to 0.22 ± 0.07, P = 0.032) but not in the LVV-control group (from 0.11 ± 0.05 to 0.10 ± 0.03, n.s.; Figure 3 ). This increase in LF:HF ratio gives indirect evidence for a shift towards sympathetic dominance in cardiac sympathovagal balance. The LF component of systolic BP increased significantly in LVV-shRNA/nNOS rats from baseline to week 3 (from 3.20 ± 0.33 to 3.66 ± 0.34 mmHg 2 , P = 0.016) but not in LVV-control rats (from 3.12 ± 0.32 to 3.21 ± 0.34 mmHg 2 , n.s.), indicating a general increase in vasomotor sympathetic drive, and consistent with the increase in renal SNA. Taken together, these observations suggest that the increased sympathetic outflow in LVV-shRNA/nNOS rats is global. This panel shows the cardiac association (integrated renal SNA signal overlaid and averaged over successive systolic beats) and the response to nasopharyngeal activation with a brief exposure to cigarette smoke (insets; smoke exposure indicated by grey arrow) of the renal SNA recordings 1 day before and 15 days after LVV-nNOS microinjection that was devoid of viruses mediating nNOS knockdown; this was consistent in all rats studied.
Immunohistochemical confirmation of vector expression
DISCUSSION
The data reported herein demonstrate, for the first time, that LVVmediated long-term knockdown of nNOS activity targeted to the PVN produces sustained increases in both renal sympathetic drive and arterial pressure in healthy conscious rats. Our observation of a 70% increase in renal SNA and a shift towards sympathetic predominance in the autonomic balance in LVV-shRNA/nNOS transfected rats suggests that the hypertension in these animals is driven, at least in part, by sympathetic actions on the kidney and heart. These results have important implications for the interpretation of findings by others that nitric oxide levels in the PVN are depressed in cardiovascular disease, and support the hypothesis that chronically reduced (endogenous) nitric oxide signalling in the PVN can cause sustained sympathetic hyperactivity (Huang et al., 2007; Schultz, 2009 ).
Consideration of the methodology
The present study used lentiviral shRNA to knock down endogenous nNOS in the PVN that revealed a long-term role for this protein in regulating the circulation. We have previously shown, using Western blot analysis, that this binary system reduces nNOS protein expression , renal SNA, low-frequency to high-frequency ratio of the R-R interval (LF:HF) and spontaneous baroreflex gain (sBRG) during baseline (days −3 to −1) and nNOS knockdown (days 15-18). # P < 0.05, nNOS versus control. Note that the LF:HF ratio is increased in nNOS versus control rats, indicating that cardiac sympathovagal tone may be decreased in cell lines in vitro by up to 82% and in vivo in dorsomedial medullary neurones by ∼55%, whereas the control construct caused no measurable effects Montero et al., 2010) , which is consistent with the nNOS knockdown we found in the PVN herein.
In the in vivo animal, it is unknown how long expression takes to reach a functionally effective reduction in nNOS protein. The use of a viral vector approach, as opposed to a knockout mouse, gives the benefit of allowing a highly restricted, circumscribed brain region to be targeted. In comparison to overexpression of nNOS, the use of knockdown is advantageous because only neurones that endogenously express nNOS will be affected, in contrast to the situation when a newly expressed exogenous protein may appear in uncontrolled concentrations as well as in cells that normally do not produce it Zheng, Liu, Li, Sharma, & Patel, 2011) . Moreover, the use of LVV permits relatively long-term (up to several months) stable expression (Coleman et al., 2003) . In addition, LVV are essentially non-immunogenic in the CNS. This may be important because proinflamatory properties of previously used adenoviral vectors (Liu & Muruve, 2003) could lead to upregulation of nNOS, complicating the interpretation of data. Although a viral vector strategy to knock down nNOS limits compensation, we cannot rule out compensatory changes, perhaps in the form of upregulation of endothelial and/or inducible nitric oxide synthase, which can also occur after surgical trauma (Petrov & Rafols, 2001 ). However, any such changes would be expected to oppose a reduction in nitric oxide, and thus, reduce the observed pressor and sympathoexcitatory responses. If this has occurred, then the magnitude of the increase in arterial pressure and renal SNA will have been underestimated.
It might be expected that multiple intrinsic physiological systems would oppose any increase in arterial pressure such as that we have observed. The fact that nNOS knockdown in the PVN of a normal adult Wistar rat is able to produce such a dramatic and sustained increase in renal SNA, with a moderate increase in arterial pressure, supports the notion of the PVN as a 'central command' centre for the sympathetic outflow (Dampney et al., 2005) . Although we did not detect any changes in the spontaneous cardiac baroreceptor reflex gain, we speculate that the baroreflex control of sympathetic outflow to the arterioles, including those in the kidney, is reset to permit adjustment of the set-point of vasomotor tone, hence arterial pressure.
Our data are compatible with the notion that the PVN is a powerful and important regulator of the long-term level of sympathetic outflow in health.
Neuronal nitric oxide synthase activity in the PVN: a major regulator of physiological levels of autonomic activity
Mechanistically, it has been shown that nitric oxide inhibits the firing of PVN neurones projecting to autonomic centres in the medulla oblongata, such as the rostral ventrolateral medulla, and spinal cord (Li et al., 2002a; Li, Zhang, & Stern, 2003) . Sutton et al. (2014) have published findings showing that as well as directly projecting to the nucleus tractus solitarii, nNOS-positive PVN neurones also directly innervate preganglionic sympathetic output neurones in the thoracic spinal cord. This suggests that nNOS-dependent alterations in PVN outflow might influence sympathetic tone via this direct pathway. Alternatively, substantial neuroanatomical and functional evidence supports nNOS-released nitric oxide driving an inhibitory (GABA A -ergic) system that regulates PVN output activity affecting sympathetic tone and arterial pressure (Dampney et al., 2005; Li et al., 2003; Patel & Zheng, 2012; Pyner, 2009) . In rats with heart failure, the inhibitory effects of nitric oxide in the PVN on sympathetic nerve discharge appear to be impaired , and this is associated with both a downregulation of nNOS via an AT 1 receptormediated mechanism (Sharma, Llewellyn, Zheng, & Patel, 2013 ) and a loss of GABAergic inhibition (Zhang, Li, & Patel, 2002) . In contrast, ectopic nNOS expression in the PVN of a rat model of heart failure has been shown to reduce the glutamatergic drive in this region (Zhang et al., 2001; Zheng et al., 2011) .
It has been suggested that nitric oxide acts via excitation of GABAergic interneurones impinging onto PVN sympathetic premotor neurones (Biancardi et al., 2011) , thereby acting as a 'brake' on sympathetic outflow (Hirooka et al., 2011; Zhang et al., 1997) . This (Wang et al., 2006b; Wang, Teschemacher, Paton, Jones, & Kasparov, 2006a) . Although confirming that nitric oxide within the PVN is important for determining the long-term level of sympathetic outflow, our results do not determine whether this occurs via direct projections or by changes in local GABAergic inhibition.
In contrast to the present study, Ramchandra, Hood, Frithiof, McKinley, and May (2013) injected muscimol or glycine into the PVN of conscious sheep and reported no change in blood pressure or renal sympathetic nerve activity, suggesting that there was no tonic sympathoexcitatory drive from the PVN regulating arterial pressure. Species differences aside, this pan-neuronal approach could be explained by simultaneous inactivation of opposing excitatory and inhibitory drives regulating sympathetic activity with a nulling out of a response on blood pressure. In contrast, our lentiviral approach used an amplified synapsin promoter that will only affect neurones (not astrocytes) and, importantly, only affects those neurones in which nNOS is active constituitively. Our findings support the presence of constituitively active nNOS preferentially affecting an inhibitory system. The presence of GABA-and nNOS-containing interneurones in the PVN (Watkins et al., 2009 ) and their close apposition provides the neuroanatomical substrate for discrete crosstalk, allowing selective activation of an inhibitory synapse onto excitatory PVN sympathoexcitatory neurones.
Our results did not show a change in cardiac baroreflex gain or HR variability, as has been previously observed with global, chronic changes to PVN neuronal activity (Geraldes, Goncalves-Rosa, Liu, Paton, & Rocha, 2014) . This suggests that nitric oxide regulation of PVN activity may not be crucial for cardiac parasympathetic activity and baroreceptor reflex control of HR. However, our data do support that nNOS activity in the PVN is an important factor regulating sympathetic activity to the heart, as indicated by alterations in the HF:LF ratio of the HR spectra, as well as vasomotor sympathetic control. We acknowledge that this will need confirmation, but our data lead us to propose that nitric oxide in the PVN predominantly modulates sympathetic rather than parasympathetic outflows.
Regulation of nNOS activity in health and disease
The factors that drive the normal expression and activity of nNOS have not been fully elucidated. Afferent connections from the nucleus tractus solitarii have been shown to impinge on GABAergic and nitric oxide-producing interneurones in the PVN (Affleck, Coote, & Pyner, 2012) , which supports a role for homeostatic reflex activity (e.g. baroreceptor, peripheral chemoreceptor and Bainbridge reflexes) in the control of sympathetic outflow via PVN nNOS pathways. At a cellular level, nNOS expression has been shown to be regulated by the inducible transcription factor c-jun (Cheng et al., 2012 (Cheng et al., , 2014 , implying that nNOS expression might be responsive to stimuli such as stress, infection and inflammation.
In disease states, nitric oxide levels are typically depleted by oxidative stress or nitric oxide synthase uncoupling (Antoniades et al., 2009; Crabtree & Channon, 2011; Moens et al., 2008) , both of which are known to occur in the brain in conditions of hypertension (Francis & Davisson, 2014; Hirooka et al., 2011; Oliveira-Sales et al., 2010; Zimmerman, Lazartigues, Sharma, & Davisson, 2004) and heart failure (Patel & Schultz, 2013; Zucker, 2006) . Together with the present data, these studies implicate insufficient nNOS signalling in the PVN as a potential causal mediator of sympathetic excess, which could underpin a plethora of disease states.
In conclusion, our data fully support the notion that nNOSgenerated nitric oxide in the PVN of Wistar rats is acting as a physiological 'brake' on sympathetic outflow. Moreover, the tonicity of the inhibitory system in the PVN provides neural plasticity, permitting the set-point control of arterial pressure to be adjusted. A future challenge will be to see in what physiological conditions this plasticity is harnessed to maintain homeostasis.
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